308 related articles for article (PubMed ID: 32187552)
1. APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin.
Uzureau S; Lecordier L; Uzureau P; Hennig D; Graversen JH; Homblé F; Mfutu PE; Oliveira Arcolino F; Ramos AR; La Rovere RM; Luyten T; Vermeersch M; Tebabi P; Dieu M; Cuypers B; Deborggraeve S; Rabant M; Legendre C; Moestrup SK; Levtchenko E; Bultynck G; Erneux C; Pérez-Morga D; Pays E
Cell Rep; 2020 Mar; 30(11):3821-3836.e13. PubMed ID: 32187552
[TBL] [Abstract][Full Text] [Related]
2. The function of apolipoproteins L (APOLs): relevance for kidney disease, neurotransmission disorders, cancer and viral infection.
Pays E
FEBS J; 2021 Jan; 288(2):360-381. PubMed ID: 32530132
[TBL] [Abstract][Full Text] [Related]
3. The Mechanism of Kidney Disease Due to APOL1 Risk Variants.
Pays E
J Am Soc Nephrol; 2020 Nov; 31(11):2502-2505. PubMed ID: 32943491
[No Abstract] [Full Text] [Related]
4. Apolipoproteins L1 and L3 control mitochondrial membrane dynamics.
Lecordier L; Heo P; Graversen JH; Hennig D; Skytthe MK; Cornet d'Elzius A; Pincet F; Pérez-Morga D; Pays E
Cell Rep; 2023 Dec; 42(12):113528. PubMed ID: 38041817
[TBL] [Abstract][Full Text] [Related]
5. APOL1 variant-associated kidney disease: from trypanosomes to podocyte cytoskeleton.
Pays E
Kidney Int; 2020 Dec; 98(6):1373-1377. PubMed ID: 32835731
[No Abstract] [Full Text] [Related]
6. The Janus-faced functions of Apolipoproteins L in membrane dynamics.
Pays E
Cell Mol Life Sci; 2024 Mar; 81(1):134. PubMed ID: 38478101
[TBL] [Abstract][Full Text] [Related]
7. Distinct APOL1 functions in trypanosomes and kidney podocytes.
Pays E
Trends Parasitol; 2022 Feb; 38(2):104-108. PubMed ID: 34887168
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.
Sharma AK; Friedman DJ; Pollak MR; Alper SL
FEBS J; 2016 May; 283(10):1846-62. PubMed ID: 26945671
[TBL] [Abstract][Full Text] [Related]
9. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
[TBL] [Abstract][Full Text] [Related]
10. Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif.
Ultsch M; Holliday MJ; Gerhardy S; Moran P; Scales SJ; Gupta N; Oltrabella F; Chiu C; Fairbrother W; Eigenbrot C; Kirchhofer D
Commun Biol; 2021 Jul; 4(1):916. PubMed ID: 34316015
[TBL] [Abstract][Full Text] [Related]
11. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
[TBL] [Abstract][Full Text] [Related]
12. APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?
Olabisi OA; Heneghan JF
Semin Nephrol; 2017 Nov; 37(6):546-551. PubMed ID: 29110762
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes.
Scales SJ; Gupta N; De Mazière AM; Posthuma G; Chiu CP; Pierce AA; Hötzel K; Tao J; Foreman O; Koukos G; Oltrabella F; Klumperman J; Lin W; Peterson AS
J Am Soc Nephrol; 2020 Sep; 31(9):2044-2064. PubMed ID: 32764142
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.
Vandorpe DH; Heneghan JF; Waitzman JS; McCarthy GM; Blasio A; Magraner JM; Donovan OG; Schaller LB; Shah SS; Subramanian B; Riella CV; Friedman DJ; Pollak MR; Alper SL
Pflugers Arch; 2023 Mar; 475(3):323-341. PubMed ID: 36449077
[TBL] [Abstract][Full Text] [Related]
15. Effect of
Haque S; Patil G; Mishra A; Lan X; Popik W; Malhotra A; Skorecki K; Singhal PC
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28385815
[TBL] [Abstract][Full Text] [Related]
16. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
[TBL] [Abstract][Full Text] [Related]
17. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
18. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
[TBL] [Abstract][Full Text] [Related]
19. APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.
Beckerman P; Susztak K
Trends Mol Med; 2018 Aug; 24(8):682-695. PubMed ID: 29886044
[TBL] [Abstract][Full Text] [Related]
20. APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress.
Wakashin H; Heymann J; Roshanravan H; Daneshpajouhnejad P; Rosenberg A; Shin MK; Hoek M; Kopp JB
BMC Nephrol; 2020 Aug; 21(1):371. PubMed ID: 32854642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
